Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia

Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related... Adv Ther (2017) 34:2585–2600 DOI 10.1007/s12325-017-0624-6 ORIGINAL RESEARCH Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia . . . Adrian Skelly Hans-Joachim Carius Vladimir Bezlyak Fred K. Chen Received: May 3, 2017 / Published online: November 21, 2017 The Author(s) 2017. This article is an open access publication December 1, 2012, and March 31, 2015, with ABSTRACT follow-up of at least 6 months. The number of ranibizumab and aflibercept units dispensed Introduction: Anti-vascular endothelial growth was adjusted for baseline patient Medica- factor therapy is the standard of care for neo- tion-Based Disease Burden Index (MBDBI) vascular age-related macular degeneration scores. No difference in the number of ranibi- (nAMD). The dosage of two licensed agents, zumab versus aflibercept units dispensed was ranibizumab and aflibercept, was established concluded if the 95% confidence interval (CI) through clinical trials; however, it is unclear if limits of the adjusted mean difference between either agent is administered as recommended in the study cohorts were 1.00 unit or less. routine clinical practice. Using pharmacy claims Results: Baseline patient MBDBI scores were data, we investigated if the dispensing patterns similar for the ranibizumab (N = http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia

Loading next page...
 
/lp/springer_journal/dispensing-patterns-of-ranibizumab-and-aflibercept-for-the-treatment-2YHU1aIZEe
Publisher
Springer Healthcare
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology
ISSN
0741-238X
eISSN
1865-8652
D.O.I.
10.1007/s12325-017-0624-6
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial